Journal ArticleOPEN ACCESS

Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?

  • Gao X
  • McDermott D
  • Michaelson M
The Oncologist (2019) 24(6) 725-727
DOI: 10.1634/theoncologist.2019-0165
5Citations
Citations of this article
25Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Combination therapies involving antiangiogenic agents plus immune checkpoint inhibitors have recently demonstrated clinical efficacy in advanced renal cell carcinoma (RCC). This commentary summarizes the clinical advances and reviews the potential implications for RCC and other advanced solid tumors.

Cite

CITATION STYLE

APA

Gao, X., McDermott, D. F., & Michaelson, M. D. (2019). Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma? The Oncologist, 24(6), 725–727. https://doi.org/10.1634/theoncologist.2019-0165

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free